In the pharmaceutical and biotechnology industries, Clean Piping plays a key role in controlling contamination risks. Discover its principles, technical requirements and the standards governing high-purity fluid networks.
Impact
In pharmaceutical and biotechnology production, every component of an installation can become a source of contamination. Piping networks play a critical role in the quality of the finished product and, ultimately, in patient safety.
It is precisely to address a critical need for standardization in the pharmaceutical and biotechnology industries that standards such as ASME BPE were created. These standards have notably formalized the best practices applicable to Clean Piping, or high-purity systems and networks.
What is Clean Piping ?
Clean Piping refers to all piping networks and systems designed, manufactured and installed to generate, store and convey process fluids that will have direct or indirect contact with the finished product : purified water, water for injection (WFI), pure steam, solvents, clean compressed air, nitrogen, etc.
The design of these systems is studied to :
- minimize, or even eliminate, impurities ;
- ensure system cleanliness ;
- guarantee the integrity of the installations ;
- ensure traceability of operations, particularly through documentation and permanent monitoring.
Unlike « conventional » industrial piping, these installations cannot rely on a standard design. They must meet precise and documented requirements in terms of :
- construction materials ;
- surface finish ;
- assembly geometry ;
- assembly techniques ;
- technical and quality documentation.
"In a GMP environment, the control of high-purity fluid networks relies on a set of technical, documentary and quality requirements. Clean Piping directly addresses this need for standardization, traceability and risk control."
Why is Clean Piping essential in the pharmaceutical and biotechnology industries ?
In a pharmaceutical plant, any contact between a process fluid and a piping surface represents a potential risk of contamination, whether microbiological, chemical or particulate.
Excessive roughness, unfavorable geometry, a poorly dimensioned dead leg or an unsuitable material can alter product quality. One of the objectives of Clean Piping is to prevent this type of situation by integrating control measures throughout the installation process.
Clean Piping is therefore part of a risk control approach, governed by standards and authorities such as :
- the FDA, Food and Drug Administration, in the United States ;
- the EMA, European Medicines Agency, in Europe ;
- ICH Q7 guidelines for active pharmaceutical ingredients ;
- Good Manufacturing Practices, GMP.
GMP requires every manufacturer to demonstrate that its installations are qualified, traceable and compliant at every stage of the installation lifecycle.
What distinguishes Clean Piping from conventional industrial piping ?
Clean Piping differs in several fundamental technical aspects.
Materials
The materials used must be compatible with the fluid conveyed, cleaning constraints, cleanliness requirements and operating conditions.
316L stainless steel is very frequently used in Clean Piping, particularly for its corrosion resistance and compatibility with aggressive cleaning processes. However, it is not the only possible material. Depending on the applications, process constraints and project specifications, other materials may be used, such as 304 stainless steel or certain polymer materials such as HDPE.
Surface finish
The internal roughness of tubes and fittings is controlled and documented in order to limit particle adhesion, contaminant retention or the potential development of biofilm.
Depending on the applications and project requirements, roughness can be specified at very low levels, for example : Ra ≤ 0.8 µm, or even lower, notably around Ra ≤ 0.51 µm or even Ra ≤ 0.38 µm for specific uses. Electropolishing may be used to improve the internal surface finish and facilitate cleaning.
Automated orbital welding
The repeatability and quality of welds are ensured through orbital welding, a technique that helps limit defects, inclusions and surface irregularities inside the joints.
In high-purity fluid networks, weld quality is a critical point. Internal defects can become retention or contamination zones that are difficult to detect through a simple external visual inspection.
Limitation and ideally elimination of dead legs
A dead leg is a section of piping connected to the main network where fluid circulation is insufficient or nonexistent, creating a risk of stagnation.
In pharmaceutical Clean Piping, dead leg management is based on a risk-based approach, taking into account the fluid, its criticality and the applicable standard or guideline (ASME BPE, ISPE, etc.).
For critical fluids such as WFI, strict requirements apply, typically dead leg ≤ 2D. For less critical applications, more flexible criteria, such as 3D to 4D, may be accepted, provided they are justified and validated.
CIP / SIP system
The installations are designed to be cleaned and/or sterilized in place, via CIP (Cleaning-In-Place) and SIP (Sterilization-In-Place) systems, without requiring systematic disassembly.
This compatibility is essential to ensure network cleanliness, reduce manual interventions and maintain installation compliance over time.
Complete documentation
Every element of the installation must be documented, traced, archived and available for audits or qualifications.
The documentation includes, among other things :
- PID, Process & Instrumentation Diagrams ;
- isometrics ;
- welding logs ;
- WPS ;
- PQR ;
- material certificates ;
- inspection reports (NDT) ;
- elements required for IQ/OQ/PQ qualification.
The regulatory framework : recognized international standards
Clean Piping installations must be carried out and qualified according to internationally recognized standards and guidelines :
| Standard / guideline | Scope |
| ASME BPE | Design, materials, finishes, assemblies, manufacturing and requirements applicable to bioprocess equipment |
| ISPE Baseline Guides | Good pharmaceutical engineering practices |
| European GMP | Regulatory framework applicable to pharmaceutical manufacturing |
| ICH Q7 | Good manufacturing practices applicable to active pharmaceutical ingredients |
| EHEDG | Recommendations relating to hygienic equipment |
Compliance with these standards and guidelines is verified during the IQ/OQ qualification phases : Installation Qualification and Operational Qualification. It must be documented and maintained throughout the entire lifecycle of the installation.
Mecalab : your Clean Piping partner for the pharmaceutical and biotechnology industries
Mecalab offers a dedicated service for pharmaceutical and biotech Clean Piping, backed by solid expertise in industrial piping, orbital welding and welded fabrication.
Our teams are involved in the realization and installation of high-purity piping networks, in compliance with the requirements applicable to pharma and biotech environments.
We support manufacturers at every operational stage of the project :
- preparation and realization of high-purity fluid networks based on established technical files ;
- manufacturing and installation in compliance with applicable standards, including ASME BPE, and GMP requirements ;
- orbital welding and welded fabrication ;
- creation and follow-up of quality documentation ;
- support for commissioning and IQ/OQ/PQ qualification phases.
Are you preparing a new construction or renovation project related to the pharmaceutical or biotech industry ?
Are you looking for a partner capable of handling the technical realization, installation and associated documentation for your high-purity piping networks ?